Display options
Cite
Baxter E, Windloch K, Gannon F, et al. Epigenetic regulation in cancer progression. Cell Biosci. 2014;4:45doi: 10.1186/2045-3701-4-45.
Baxter, E., Windloch, K., Gannon, F., & Lee, J. S. (2014). Epigenetic regulation in cancer progression. Cell & bioscience, 445. https://doi.org/10.1186/2045-3701-4-45
Baxter, Eva, et al. "Epigenetic regulation in cancer progression." Cell & bioscience vol. 4 (2014): 45. doi: https://doi.org/10.1186/2045-3701-4-45
Baxter E, Windloch K, Gannon F, Lee JS. Epigenetic regulation in cancer progression. Cell Biosci. 2014 Aug 19;4:45. doi: 10.1186/2045-3701-4-45. eCollection 2014. PMID: 25949794; PMCID: PMC4422217.
Copy Download .nbib Format: NLM
Share it on

Cell Biosci. 2014 Aug 19;4:45. doi: 10.1186/2045-3701-4-45. eCollection 2014.

Epigenetic regulation in cancer progression.

Cell & bioscience

Eva Baxter, Karolina Windloch, Frank Gannon, Jason S Lee

Affiliations

  1. QIMR Berghofer Medical Research Institute, Control of Gene Expression Laboratory, Herston Rd, 4006 Herston, QLD, Australia.

PMID: 25949794 PMCID: PMC4422217 DOI: 10.1186/2045-3701-4-45

Abstract

Cancer is a disease arising from both genetic and epigenetic modifications of DNA that contribute to changes in gene expression in the cell. Genetic modifications include loss or amplification of DNA, loss of heterozygosity (LOH) as well as gene mutations. Epigenetic changes in cancer are generally thought to be brought about by alterations in DNA and histone modifications that lead to the silencing of tumour suppressor genes and the activation of oncogenic genes. Other consequences that result from epigenetic changes, such as inappropriate expression or repression of some genes in the wrong cellular context, can also result in the alteration of control and physiological systems such that a normal cell becomes tumorigenic. Excessive levels of the enzymes that act as epigenetic modifiers have been reported as markers of aggressive breast cancer and are associated with metastatic progression. It is likely that this is a common contributor to the recurrence and spread of the disease. The emphasis on genetic changes, for example in genome-wide association studies and increasingly in whole genome sequencing analyses of tumours, has resulted in the importance of epigenetic changes having less attention until recently. Epigenetic alterations at both the DNA and histone level are increasingly being recognised as playing a role in tumourigenesis. Recent studies have found that distinct subgroups of poor-prognosis tumours lack genetic alterations but are epigenetically deregulated, pointing to the important role that epigenetic modifications and/or their modifiers may play in cancer. In this review, we highlight the multitude of epigenetic changes that can occur and will discuss how deregulation of epigenetic modifiers contributes to cancer progression. We also discuss the off-target effects that epigenetic modifiers may have, notably the effects that histone modifiers have on non-histone proteins that can modulate protein expression and activity, as well as the role of hypoxia in epigenetic regulation.

Keywords: Acetylation; Cancer; DNA methylation; Demethylation; Epigenetics; Histone modifications; Hypoxia; Transcription

References

  1. N Engl J Med. 2010 Dec 16;363(25):2424-33 - PubMed
  2. Development. 1998 Mar;125(5):889-97 - PubMed
  3. Nat Rev Cancer. 2004 Feb;4(2):143-53 - PubMed
  4. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5237-42 - PubMed
  5. Br J Haematol. 2009 Jun;145(6):788-800 - PubMed
  6. Hum Genet. 1994 Nov;94(5):491-6 - PubMed
  7. Cancer Res. 1997 Jun 1;57(11):2229-37 - PubMed
  8. Proc Natl Acad Sci U S A. 1982 Jun;79(11):3418-22 - PubMed
  9. Nat Genet. 2009 Jan;41(1):125-9 - PubMed
  10. Cancer Res. 1988 Mar 1;48(5):1159-61 - PubMed
  11. Pathol Int. 2012 Mar;62(3):182-90 - PubMed
  12. J Clin Invest. 2012 Apr;122(4):1469-86 - PubMed
  13. Science. 2011 Sep 2;333(6047):1303-7 - PubMed
  14. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 - PubMed
  15. Trends Biochem Sci. 2010 Nov;35(11):618-26 - PubMed
  16. Cancer Res. 2009 Aug 1;69(15):6315-21 - PubMed
  17. Nature. 2005 Jun 30;435(7046):1262-6 - PubMed
  18. Cancer Res. 2007 Feb 1;67(3):946-50 - PubMed
  19. Nat Rev Cancer. 2010 Jul;10(7):457-69 - PubMed
  20. Cell. 1999 Oct 29;99(3):247-57 - PubMed
  21. N Engl J Med. 2009 May 28;360(22):2289-301 - PubMed
  22. Mol Cell. 2012 Nov 30;48(4):572-86 - PubMed
  23. Nature. 2004 Nov 18;432(7015):353-60 - PubMed
  24. Nat Commun. 2011;2:241 - PubMed
  25. Nat Genet. 2009 May;41(5):521-3 - PubMed
  26. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11733-7 - PubMed
  27. Gene. 2002 May 1;289(1-2):41-8 - PubMed
  28. Nucleic Acids Res. 1983 Oct 11;11(19):6883-94 - PubMed
  29. Genes Dev. 1995 May 15;9(10):1211-22 - PubMed
  30. Cell. 2006 Apr 21;125(2):315-26 - PubMed
  31. Nature. 2007 Jul 5;448(7149):87-91 - PubMed
  32. Nature. 2000 Jan 6;403(6765):41-5 - PubMed
  33. Nature. 2008 Mar 6;452(7183):112-5 - PubMed
  34. Cancer Res. 2006 Sep 15;66(18):9009-16 - PubMed
  35. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 - PubMed
  36. Cancer Res. 1997 Mar 1;57(5):808-11 - PubMed
  37. Mol Cell. 2010 Oct 22;40(2):294-309 - PubMed
  38. Genes Chromosomes Cancer. 2002 Sep;35(1):1-10 - PubMed
  39. Nat Genet. 1999 Feb;21(2):163-7 - PubMed
  40. Genes Dev. 2002 Jan 1;16(1):6-21 - PubMed
  41. Mol Cell Biol. 1992 Dec;12(12):5447-54 - PubMed
  42. Cancer Cell. 2010 Dec 14;18(6):553-67 - PubMed
  43. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 - PubMed
  44. Science. 2011 Sep 2;333(6047):1300-3 - PubMed
  45. Cancer Cell. 2013 Jun 10;23 (6):839-52 - PubMed
  46. Blood. 2010 Nov 4;116(18):3564-71 - PubMed
  47. Genes Dev. 2012 Jan 1;26(1):37-42 - PubMed
  48. Cancer Cell. 2010 May 18;17(5):510-22 - PubMed
  49. Nat Rev Cancer. 2002 Jan;2(1):38-47 - PubMed
  50. Nat Genet. 2006 Jul;38(7):787-93 - PubMed
  51. Oncogene. 2002 Aug 12;21(35):5380-7 - PubMed
  52. Nature. 2002 Oct 10;419(6907):624-9 - PubMed
  53. Nature. 2007 Nov 1;450(7166):119-23 - PubMed
  54. Sci Transl Med. 2014 Mar 26;6(229):229ra41 - PubMed
  55. Genes Dev. 2009 May 15;23(10):1171-6 - PubMed
  56. Proc Natl Acad Sci U S A. 2007 May 8;104(19):8023-8 - PubMed
  57. Nat Rev Cancer. 2008 Dec;8(12):967-75 - PubMed
  58. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1929-33 - PubMed
  59. Oncogene. 1993 Apr;8(4):1063-7 - PubMed
  60. Mol Cell. 2003 Dec;12(6):1591-8 - PubMed
  61. Science. 1994 Mar 18;263(5153):1625-9 - PubMed
  62. J Biol Chem. 2011 Oct 14;286(41):35334-8 - PubMed
  63. Cell. 2004 Dec 29;119(7):941-53 - PubMed
  64. Cancer Res. 2010 Oct 15;70(20):7830-40 - PubMed
  65. Oncogene. 2013 Jan 31;32(5):663-9 - PubMed
  66. Science. 1985 Apr 12;228(4696):187-90 - PubMed
  67. Nature. 2008 Mar 6;452(7183):45-50 - PubMed
  68. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4273-8 - PubMed
  69. Biochem Biophys Res Commun. 2008 May 30;370(2):230-4 - PubMed
  70. Oncogene. 2009 Jan 15;28(2):184-94 - PubMed
  71. Nature. 2009 Nov 19;462(7271):315-22 - PubMed
  72. Nature. 2007 Sep 6;449(7158):105-8 - PubMed
  73. Science. 2001 Aug 10;293(5532):1074-80 - PubMed
  74. Cell. 2007 Apr 6;129(1):111-22 - PubMed
  75. N Engl J Med. 1988 Sep 1;319(9):525-32 - PubMed
  76. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12 ):6870-5 - PubMed
  77. Mol Cell. 2010 Jul 9;39(1):71-85 - PubMed
  78. Nature. 2010 Dec 9;468(7325):839-43 - PubMed
  79. Curr Opin Genet Dev. 2010 Feb;20(1):51-6 - PubMed
  80. Oncogene. 2007 Feb 8;26(6):802-12 - PubMed
  81. Nature. 2014 Feb 27;506(7489):445-50 - PubMed
  82. Nature. 2006 Nov 30;444(7119):629-32 - PubMed
  83. Science. 2009 May 15;324(5929):930-5 - PubMed
  84. Cell. 2011 Apr 29;145(3):423-34 - PubMed
  85. J Biol Chem. 2010 Mar 26;285(13):9636-41 - PubMed
  86. Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13510-5 - PubMed
  87. Cancer Cell. 2011 Jul 12;20(1):11-24 - PubMed

Publication Types